- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04132830
HIV Exposure In Utero and Metabolic Disease Risk in HIV-Negative Young Adults (HIV HEREDITY)
August 8, 2023 updated by: Lindsay Fourman, MD, Massachusetts General Hospital
Globally, over 1 million babies are born to mothers with HIV each year.
With the advent of prenatal antiretroviral therapy, up to 98% of these individuals may be HIV-exposed uninfected (HEU).
A growing literature suggests that in utero HIV exposure - even in the absence of subsequent infection - may be associated with adverse health outcomes in infancy and childhood.
However, there is little information about the long-term health implications of in utero HIV exposure later in life, such as into adulthood.
In this study, for the first time, we seek to prospectively evaluate metabolic and immune indices among HEU young adults as compared to well-matched HIV-unexposed uninfected controls.
This study serves as a necessary first step toward optimizing clinical care for this expanding and aging HEU population, including the implementation of novel screening and prevention strategies.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
300
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lindsay T Fourman, MD
- Phone Number: 617-643-4590
- Email: LFourman@partners.org
Study Contact Backup
- Name: Isabel Zheng
- Phone Number: 67-643-4420
- Email: IZheng@partners.org
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Lindsay T Fourman, MD
- Phone Number: 617-643-4590
- Email: LFourman@partners.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Probability Sample
Study Population
We are recruiting mothers who had HIV during pregnancy and their HIV-negative young adult offspring (18-30 years old).
We are also recruiting mothers and their young adult offspring without HIV to serve as controls.
Description
INCLUSION CRITERIA:
HIV-Exposed Uninfected (HEU) Mother-Young Adult Dyads
- Male or female young adult, 18-30 years old
- Documentation of HIV infection in mother with date of diagnosis preceding young adult birth date
- Negative HIV test in young adult
Control Mother-Young Adult Dyads
- Matching to HEU dyad
- Negative HIV test in mother and young adult
EXCLUSION CRITERIA:
All Young Adults
- History of being adopted
- Pregnancy within 6 months or active nursing
- Change in blood glucose or blood pressure medication within 3 months
- Change in estrogen or testosterone therapy within 3 months
- Glucocorticoids (except steroid inhalers or creams) within 3 months
- Antiretroviral therapy use within 6 months (i.e., prophylaxis)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
HIV-Exposed Uninfected Dyads
Mothers who had HIV during pregnancy and their HIV-negative young adult offspring
|
HIV-Unexposed Uninfected Dyads
Mothers and young adults without HIV
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body mass index (BMI)
Time Frame: Baseline
|
Baseline
|
|
Activated CD8+ T cells
Time Frame: Baseline
|
Flow cytometry
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Abdominal fat mass
Time Frame: Baseline
|
Dual-energy x-ray absorptiometry
|
Baseline
|
Glucose tolerance
Time Frame: Baseline
|
Oral glucose tolerance test
|
Baseline
|
Lipids
Time Frame: Baseline
|
Standard lipid panel (including HDL, triglycerides)
|
Baseline
|
Blood pressure
Time Frame: Baseline
|
Systolic and diastolic
|
Baseline
|
Hepatic fat content
Time Frame: Baseline
|
Transient elastography
|
Baseline
|
Hepatic fibrosis
Time Frame: Baseline
|
Transient elastography
|
Baseline
|
Immune cell subsets
Time Frame: Baseline
|
Flow cytometry
|
Baseline
|
Inflammatory markers
Time Frame: Baseline
|
ELISA
|
Baseline
|
Frequency of Asthma
Time Frame: Baseline, Ever
|
Baseline, Ever
|
|
DNA methylation patterns
Time Frame: Baseline
|
Epigenome-wide analysis
|
Baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Lindsay T Fourman, MD, Massachusetts General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2019
Primary Completion (Estimated)
July 1, 2024
Study Completion (Estimated)
July 1, 2024
Study Registration Dates
First Submitted
October 7, 2019
First Submitted That Met QC Criteria
October 16, 2019
First Posted (Actual)
October 21, 2019
Study Record Updates
Last Update Posted (Actual)
August 14, 2023
Last Update Submitted That Met QC Criteria
August 8, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019P000629
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV-exposed Uninfected
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
Michigan State UniversityJohns Hopkins University; Eunice Kennedy Shriver National Institute of Child... and other collaboratorsActive, not recruitingHIV Infections | HIV Exposed Uninfected | HUU Unexposed UninfectedMalawi, Uganda
-
Duke UniversityCatholic Relief ServicesCompletedEarly Childhood Development in HIV-Exposed ChildrenCameroon
-
University of FloridaNational Aeronautics and Space Administration (NASA)CompletedMicrogravity Exposed Endothelial CellsUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)Completed
-
University of Colorado, DenverNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcohol Exposed PregnancyUnited States
-
Nationwide Children's HospitalCompletedExposed to AnesthesiaUnited States
-
Tel-Aviv Sourasky Medical CenterCompletedOccupational Exposed Population
-
Baylor UniversityWayne State University; University of Texas at AustinRecruitingRisk for an Alcohol-Exposed Pregnancy | Risk for Marijuana-Exposed Pregnancy | Risk for Substance-Exposed Pregnancy | HIV Risk | Sexually Transmitted Infection RiskUnited States
-
University Hospital, Clermont-FerrandCompleted